Mathew Brian Maier

Title: Mathew Brian Maier: Innovator in Protein Tyrosine Phosphatase Inhibitors

Introduction

Mathew Brian Maier is an innovative inventor based in the United States. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that act as human protein tyrosine phosphatase beta (HPTP-β) inhibitors. His work focuses on regulating angiogenesis, which is crucial for various biological processes.

Latest Patents

Mathew Brian Maier currently holds 0 patents. However, his notable patent is titled "Human Protein Tyrosine Phosphatase Inhibitors And Methods Of Use." This patent discusses compounds that effectively inhibit HPTP-β, thereby regulating angiogenesis. The disclosure also includes compositions comprising these inhibitors and methods for their application in regulating angiogenesis.

Career Highlights

Mathew Brian Maier is associated with Aerpio Therapeutics, Inc., a company dedicated to advancing innovative therapies. His work at Aerpio Therapeutics focuses on the development of treatments that target critical pathways in human health.

Collaborations

Mathew has collaborated with notable colleagues, including Jeffrey Lyle Gray and Cynthia Monesa Clark. These collaborations have likely contributed to the advancement of research in the field of protein tyrosine phosphatase inhibitors.

Conclusion

Mathew Brian Maier is a dedicated inventor whose work in protein tyrosine phosphatase inhibitors holds promise for future therapeutic applications. His contributions to the field are noteworthy, and his ongoing research may lead to significant advancements in medical science.